Merck anesthesia-reversal agent faces new delay<p><a href="http://news.yahoo.com/merck-anesthesia-reversal-agent-faces-delay-135805996--finance.html"><img src="http://l1.yimg.com/bt/api/res/1.2/5WfVE8b2fuuIzf0Mc1GAGQ--/YXBwaWQ9eW5ld3M7Zmk9ZmlsbDtoPTg2O3E9ODU7dz0xMzA-/http://media.zenfs.com/en_us/News/Reuters/2013-03-15T135805Z_1_CBRE92E12SW00_RTROPTP_2_SCHERINGPLOUGH-MERCK.JPG" width="130" height="86" alt="A view of the Merck & Co. campus in Linden, New Jersey" align="left" title="A view of the Merck & Co. campus in Linden, New Jersey" border="0" /></a>By Ransdell Pierson (Reuters) - The Food and Drug Administration will not complete its review of Merck & Co's experimental medicine to reverse the effects of anesthesia until the second half of 2013, representing a three-month delay, the drugmaker said. Merck acquired the product, called sugammadex, through its merger in 2009 with Schering-Plough Corp. The product has faced numerous regulatory delays but is deemed by many analysts and doctors to be one of the biggest advances in anesthesia in decades. ...</p><br clear="all"/>
Source: Merck anesthesia-reversal agent faces new delay (http://news.yahoo.com/merck-anesthesia-reversal-agent-faces-delay-135805996--finance.html)